4S2P

Crystal structure of unbound OXA-48

Summary for 4S2P

• Entry DOI: 10.2210/pdb4s2p/pdb
• Related: 3HBR
• Descriptor: Beta-lactamase (2 entities in total)
• Functional Keywords: hydrolase
• Biological source: Klebsiella pneumoniae
• Total number of polymer chains: 2
• Total formula weight: 60879.45

Authors

King, D.T.,Strynadka, N.C.J. (deposition date: 2015-01-21, release date: 2015-02-25, Last modification date: 2017-11-22)

Primary citation

King, D.T.,King, A.M.,Lal, S.M.,Wright, G.D.,Strynadka, N.C.
Molecular Mechanism of Avibactam-Mediated beta-Lactamase Inhibition.
ACS Infect Dis, 1:175-184, 2015

PubMed Abstract: Emerging β-lactamase-mediated resistance is threatening the clinical utility of the single most prominent class of antibacterial agents used in medicine, the β-lactams. The diazabicyclooctane avibactam is able to inhibit a wider range of serine β-lactamases than has been previously observed with β-lactamase inhibitors such as the widely prescribed clavulanic acid. However, despite its broad-spectrum activity, variable levels of inhibition have been observed for molecular class D β-lactamases. In order to better understand the molecular basis and spectrum of inhibition by avibactam, we provide structural and mechanistic analysis of the compound in complex with important class A and D serine β-lactamases. Herein, we reveal the 1.7- and 2.0-Å-resolution crystal structures of avibactam covalently bound to class D β-lactamases OXA-10 and OXA-48. Furthermore, a kinetic analysis of key active-site mutants for class A β-lactamase CTX-M-15 allows us to propose a validated mechanism for avibactam-mediated β-lactamase inhibition including a unique role for S130, which acts as a general base. This study provides molecular insights that will aid in the design and development of avibactam-based chemotherapeutic agents effective against emerging drug-resistant microorganisms.

PubMed: 27622530
DOI: 10.1021/acsinfecdis.5b00007

Experimental method

X-RAY DIFFRACTION (1.7 Å)